1.Van der Heijde D, Maksymovych WP. Spondiloarthritis: state of the art and future. Ann Rheum Dis 2010; 69: 949–54.
2. Slobodin G, Rozenbaum M, Boulman N et al. Varied presentations of enthesopaty. Semin Arthritis Rheum 2007; 37: 119–26.
3. Resnick D, Niwayama G. Entheses and enthesopathy. Anatomical, pathological and radiological correlation. Radiology 1983; 146: 1–9.
4. Benjamin M, McGonagle D. The anatomical basis for disease localization in seronegative spondylopathy at enthesis and related sites. J Anat 2001; 199: 503–26.
5. Helliwell P, Porter G. Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis. Skeletal Radiol 2007; 36: 1061–6.
6. Balint PV, Kane D, Wilson H et al. Ultrasonography of entheseal insertions in the lower limb in spondyloathropathy. Ann Rheum Dis 2002; 61: 905–10.
7. D’Agostino MA, Said-Nahal R, Hac-Quard-Bouder C et al. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthr Rheum 2003; 48: 523–33.
8. Eshed I, Bollow M, McGonagle DG et al. MRI of enthesitis of the appendicular skeleton in spondiloarthritis. Ann Rheum Dis 2007; 66: 1553–9.
9. McGonagle D, Gibbon W, O’Connor P et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthr Rheum 1998; 41: 694–700.
10. D’Agostino MA, Breban M, Said-Nahal R et al. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthr Rheum 2002; 46: 840–1.
11. Oliviery I, Scarano E, Padula A et al. Switching tumor necrosis factor alpha inhibititors in HLA-B 27-associated severe heel enthesitis. Arthr Rheum 2007; 57: 1572–4.
12. Oliviery I, Scarano E, Gigliotti P et al. Successful treatment of juvenile-onset HLA-B27 –associated severe and refractory heel enthesitis with adalimumab documented by magnetic resonance imaging. Rheumatology (Oxford) 2006; 45: 1315–7.
13. Inman RD, Davis JCJr, Van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase 111 trial. Arthr Rheum 2008; 58: 3402–12.
14. Davis JC, Van der Heijde D, Braun J et al. Recombinant human tumor ntcrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–6.
15. Zochling J, Van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442–52.
16. Wanders A, Van der Heijde D, Landewe R et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthr Rheum 2005; 52: 1756–65.
17. Sieper J, Klopsch T, Richter M et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomized, double-blind, cjytrolled study. Ann Rheum Dis 2008; 67: 323–9.
18. Ревматология. Национальное руководство. Под ред. Е.Л.Насонова, В.А.Насоновой, М.: ГЭОТАР-Медиа, 2008; с. 345.
19. Rainsford K. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Cur Med Res Opin 2006; 22: 1161–70.
20. Rainsford K. Current status of the therapeutic uses and actions of the prefential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 2006; 14: 120–37.
21. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritis Cartilage Drugs 1993; 43 (Suppl. 1): 34–9.
22. Wober W, Rahlfs V, Buchi N et al. Comparative efficacy and safety of the NSAIDs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendonitis. Int J Clin Pract 1998; 52: 169–75.
23. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from Northern Italian area. Drug safety 2001; 24: 1081–90.
24. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А. и др. Оценка частоты развития побочных эффектов при длительном использовании нимесулида в реальной клинической практике. МРЖ. 2009; 17 (21): 1466–72.
25. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxity associated with nimesulide and other NSAIDs. Br med J 2003; 327: 18–22.
26. Алексеева Л.И., Каратеев А.Е., Попкова Т.В., Новикова Д.С., Шарапова Е.П., Маркелова Е.П., Насонов Е.Л. Эффективность и безопасность длительного применения нимесулида у больных остеоартрозом: результаты 12-месячного открытого контролируемого исследования ДИНАМО (Длительное Использование Нимесулида при Артрозе: Многофакторная Оценка). Научно-практическая ревматология. 2009; 4.

Р.М.Балабанова 

ФГБУ НИИ ревматологии РАМН, Москва